Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which comes first? new study aims to optimize AML treatment sequence

NCT ID NCT05401097

Recruiting now Disease control Sponsor: Alice Mims Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus venetoclax) works better than the reverse order. About 125 participants who cannot have intensive chemotherapy will be randomly assigned to one of the two sequences. The goal is to see which order leads to better disease control and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ivosidenib, enasidenib, azacitidine, venetoclax
What this could lead to
If successful, this study could identify the best sequence of targeted drugs and standard therapy to improve outcomes for older AML patients with IDH mutations.
What could go wrong
This is a phase II trial with only 125 participants, so results may not apply broadly. The study compares treatment order, not a new drug, so benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UNC Hospitals, University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

    Contact Email: •••••@•••••

  • UT Southwestern Medical Center at Dallas

    RECRUITING

    Dallas, Texas, 75235, United States

  • University of Colorado

    RECRUITING

    Aurora, Colorado, 80205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.